Atorvastatin is an HMG-CoA reductase inhibitor extensively utilized to modify lipid profiles and reduce the absolute risk of major cardiovascular events. By blocking the hepatic enzyme responsible for cholesterol synthesis, it significantly lowers low density lipoprotein cholesterol while providing plaque stabilizing effects within the arterial walls. While highly effective, some individuals report myalgia or localized muscle weakness, which warrants professional clinical evaluation to rule out rare but severe conditions like rhabdomyolysis. Adherence to daily dosing schedules, coupled with a diet low in saturated fats, maximizes the therapeutic outcomes. Routine lipid panels are standard practice to monitor efficacy and ensure target cholesterol markers are safely reached.